A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

Updated on 24 January 2020
cognitive impairment
movement disorder


This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive impairment.


Condition Parkinson's disease, Parkinson's disease, Neurologic Disorders, Parkinson's Disease and Cognitive Impairment
Clinical Study IdentifierTX218034
Last Modified on24 January 2020


Yes No Not Sure

Inclusion Criteria

Diagnosis of Parkinson's Disease (PD), with at least 1 year of PD symptoms
Diagnosis of PD with mild cognitive impairment (PD-MCI) or probable or possible Parkinson's disease dementia according to Movement Disorder Society's Clinical Diagnostic criteria
Score on the Montreal Cognitive Assessment (MoCA) of 13-25
Modified Hoehn and Yahr Stages 1-4
Modified Hachinski Ischemic Scale (MHIS) score of 4 or less

Exclusion Criteria

History of blood coagulation disorders or hypercoagulability
Current use of anticoagulant therapy. Use of antiplatelet drugs (e.g., aspirin or clopidogrel) is acceptable
Prior hypersensitivity reaction to any human blood product or any IV infusion
Treatment with any human blood product, including transfusions and IV immunoglobulin, during the 6 months prior to screening
History of immunoglobulin A, haptoglobin, or C1 inhibitor deficiency; stroke, anaphylaxis, or thromboembolic complications of IV immunoglobulins
Heart disease, as evidenced by myocardial infarction, unstable, new onset or severe angina, or congestive heart failure in the 6 months prior to dosing Hemoglobin < 10 g/dL in women and < 11 g/dL in men
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note